JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
129.36
+1.08 (+0.84%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close128.28
Open128.52
Bid129.02 x 1800
Ask129.47 x 1000
Day's Range127.65 - 129.49
52 Week Range118.62 - 148.99
Volume5,149,230
Avg. Volume9,786,730
Market Cap346.941B
Beta (3Y Monthly)0.62
PE Ratio (TTM)227.35
EPS (TTM)0.57
Earnings DateJan 22, 2019
Forward Dividend & Yield3.60 (2.81%)
Ex-Dividend Date2019-02-25
1y Target Est146.39
Trade prices are not sourced from all markets
  • J&J raises prices on around two dozen drugs
    Yahoo Finance Video5 days ago

    J&J raises prices on around two dozen drugs

    Johnson & Johnson raised U.S. prices on around two dozen of its top selling prescription drugs. Yahoo Finance's Adam Shapiro, Julie Hyman and Andy Serwer discuss with Emily McCormick who gives the latest.

  • WW downgraded, Google’s board faces lawsuits, J&J hikes some prices
    Yahoo Finance Video5 days ago

    WW downgraded, Google’s board faces lawsuits, J&J hikes some prices

    WW, Google, Johnson & Johnson, JPMorgan Chase and Activision Blizzard are the companies to watch.

  • Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
    Zacks10 hours ago

    Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $129.36, moving +0.84% from the previous trading session.

  • Benzinga16 hours ago

    Cannabis Company Avicanna Eyes Canadian IPO

    Avicanna focuses on several product categories, including plant-derived cannabinoid pharmaceuticals, phytotherapeutics, dermacosmetics and extracts. In 2017, Avicanna became the first marijuana company to be accepted into Johnson & Johnson (NYSE: JNJ)'s JLABS @ Toronto, an incubation life science center. Last year, the company acquired controlling interests in Sativa Nativa and Santa Marta Golden Hemp, in which it has 70-percent and 60-percent stakes, respectively.

  • Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?
    Zacks17 hours ago

    Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?

    Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Why Geron Stock Dropped 44% in 2018
    Motley Fool19 hours ago

    Why Geron Stock Dropped 44% in 2018

    Johnson & Johnson's decision to hand back imetelstat's rights caused Geron's share price to crumble last year.

  • TheStreet.com20 hours ago

    Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

    Have you ever watched a top five economy in terms of nominal GDP try to stay on it's feet as other "top fives" inflict harm not only upon each other, but upon themselves? You may recall that the export driven German economy had contracted q/q in Q3 2018. At growth of 1.5% for the year, the German economy grew at the slowest pace since 2013, but the implication, which is a far more significant takeaway would be that the engine behind Eurozone growth did not fall into recession in late 2018.

  • Markit20 hours ago

    See what the IHS Markit Score report has to say about Johnson & Johnson.

    # Johnson & Johnson ### NYSE:JNJ View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for JNJ with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting JNJ. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $16.11 billion over the last one-month into ETFs that hold JNJ are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. JNJ credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Is Teva Pharmaceutical Industries Limited Stock a Bargain?
    Motley Foolyesterday

    Is Teva Pharmaceutical Industries Limited Stock a Bargain?

    Teva's shares were unfairly punished last month.

  • Reutersyesterday

    U.S. lawmaker launches investigation into pharma drug pricing

    A top U.S. lawmaker launched an investigation into pharmaceutical industry pricing practices on Monday, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices. Representative Elijah Cummings, who chairs the House Oversight Committee, sent letters to 12 drugmakers seeking information on price increases, investment in research and development, and corporate strategies to preserve market share and pricing power, his office said in a statement.

  • House Dems announce sweeping investigation of drug pricing
    Associated Press2 days ago

    House Dems announce sweeping investigation of drug pricing

    House Democrats announced a sweeping investigation Monday of the pharmaceutical industry's pricing practices, jockeying for the upper hand with the Trump administration on an issue that concerns Americans across the political spectrum. Oversight and Reform Committee Chairman Elijah Cummings said he's sent letters to 12 major drugmakers seeking detailed information and documents about pricing practices for brand-name drugs to treat diseases including cancer, diabetes, kidney failure and nerve pain. Cummings, a Maryland Democrat, said he wants to find out why prices have increased so dramatically for some existing medications, as well as how drug companies determine the prices of newly introduced medicines.

  • CNBC2 days ago

    House Democrats launch drug-pricing probe into a dozen major health-care companies

    AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.

  • A Look at Dow ETF Ahead of Q4 Earnings
    Zacks2 days ago

    A Look at Dow ETF Ahead of Q4 Earnings

    Let's delve into the Q4 earnings picture that will likely set up the movement of Dow Jones ETF in the coming days.

  • Stock Market Power Rankings: Amazon Back on Top
    Motley Fool3 days ago

    Stock Market Power Rankings: Amazon Back on Top

    They're big, beautiful, and ranked from 1 to 50.

  • Business Wire4 days ago

    ATTENTION JNJ EMPLOYEES: Zamansky LLC Investigates Possible ERISA Violations in the Johnson & Johnson Savings Plan

    Zamansky LLC investigates Johnson & Johnson Inc. (JNJ) (“J&J” or the “Company”) on behalf of its current and former employees for potential violations of the federal Employee Retirement Income Security Act (“ERISA”) in the J&J Savings Plan (the “Plan”). Zamansky LLC is a leading stock law firm with a practice in securities fraud, ERISA and employment class actions.

  • Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018
    Motley Fool4 days ago

    Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018

    A reversal of fortunes made last year one for the record books.

  • Johnson & Johnson Recommends Rejection Of Below-Market "Mini-Tender" Offer By Peer & Peri LLC
    PR Newswire4 days ago

    Johnson & Johnson Recommends Rejection Of Below-Market "Mini-Tender" Offer By Peer & Peri LLC

    NEW BRUNSWICK, N.J. , Jan. 11, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) received notice of an unsolicited "mini-tender" offer by Peer & Peri LLC (Peer & Peri) to purchase up to 30,000 ...

  • Why This Group Is 'An Attractive Destination For Investors' In 2019
    Investor's Business Daily4 days ago

    Why This Group Is 'An Attractive Destination For Investors' In 2019

    Medical technology stalwarts Abbott Laboratories, Johnson & Johnson and Medtronic will likely face exchange-rate headwinds in 2019, an analyst said Friday. But he stayed bullish on medtech.

  • Why This IBD Stock Of The Day Broke Out Despite Biotech Turbulence
    Investor's Business Daily4 days ago

    Why This IBD Stock Of The Day Broke Out Despite Biotech Turbulence

    Vertex Pharmaceuticals is the IBD Stock Of The Day as the leading biotech stock broke out in above-average volume The biotech is a leader in treatments for cystic fibrosis, a lung disease.

  • Johnson & Johnson Announces completion of Offer for Ci:z Holdings Co., Ltd.
    PR Newswire5 days ago

    Johnson & Johnson Announces completion of Offer for Ci:z Holdings Co., Ltd.

    NEW BRUNSWICK, N.J., Jan. 11, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that the conditions to its public tender offer for all of the outstanding shares of Ci:z Holdings Co., Ltd. (4924.T) (the "Company") not already held by Johnson & Johnson or its affiliates that was previously announced on October 23, 2018, have been satisfied and the offering period for the tender offer has expired.

  • 4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019
    Zacks5 days ago

    4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019

    Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.

  • Surgeons fear pelvic mesh lawsuits will spook patients
    Associated Press5 days ago

    Surgeons fear pelvic mesh lawsuits will spook patients

    SEATTLE (AP) — Doctors who specialize in female pelvic medicine say lawsuits by four states, including Washington and California, over products used to treat pelvic floor disorders and incontinence might scare patients away from the best treatment options — or maybe even push the products off the market.

  • Johnson & Johnson raises U.S. prices on around two dozen drugs
    Reuters5 days ago

    Johnson & Johnson raises U.S. prices on around two dozen drugs

    Johnson & Johnson (JNJ.N) raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among its top-selling products. J&J joined many other companies that raised U.S. prices on hundreds of prescription medicines earlier this month. Most of the J&J increases were between 6 percent and 7 percent, according to data from Rx Savings Solutions, which helps health plans and employers seek lower cost prescription medicines.

  • Reuters5 days ago

    J&J raises U.S. prices on around two dozen drugs

    Johnson & Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among its top-selling products. J&J joined many other companies that raised U.S. prices on hundreds of prescription medicines earlier this month. Most of the J&J increases were between 6 percent and 7 percent, according to data from Rx Savings Solutions, which helps health plans and employers seek lower cost prescription medicines.

  • Benzinga6 days ago

    20 Women Set To Dominate The International Cannabis Space In 2019

    Not long ago, the cannabis industry could take pride in the higher-than-usual percentage of C-suite positions occupied by women, with roughly 1-in-3 of these posts held by a woman. Fortunately, many of the women who are in positions of power within the cannabis industry are fighting back, fiercely seeking to advance female representation in the industry. In an attempt to honor them, Benzinga is highlighting 20 women set to dominate the international cannabis space in 2019.